Last Updated: 18 Sep 2024
Executive Summary
Jazz Pharmaceuticals PLC (JAZZ) is a biopharmaceutical company with a strong financial performance and promising growth prospects. The company has a market capitalization of $6.77 billion and trades on the NASDAQ exchange. The latest stock price is $111.55. Jazz Pharmaceuticals has a trailing price-to-earnings (P/E) ratio of 18.57 and a forward P/E ratio of 5.77. The company's financial performance is driven by its strong revenue growth and profitability.
Company Overview
Jazz Pharmaceuticals is headquartered in Dublin, Ireland, and has operations in the United States, Europe, and internationally. The company focuses on developing and marketing pharmaceutical products for various unmet medical needs. Jazz Pharmaceuticals' product portfolio includes treatments for oncology, hematology, and neuroscience.
Fundamental Analysis
Jazz Pharmaceuticals has a strong financial performance. The company's revenue has grown at a compound annual growth rate (CAGR) of 10.5% over the past five years. In 2023, the company reported revenue of $3.91 billion, up 6.9% year-over-year. Jazz Pharmaceuticals' profitability has also improved in recent years. The company's operating margin has expanded from 15.9% in 2018 to 19.5% in 2023.
Jazz Pharmaceuticals has a strong balance sheet. The company has $1.42 billion in cash and equivalents and $2.5 billion in debt. The company's debt-to-equity ratio is 0.58, which is below the industry average.
Technical Analysis
Jazz Pharmaceuticals' stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is 62, which indicates that the stock is overbought.
Short Term Outlook
Jazz Pharmaceuticals' stock price is likely to continue to trend higher in the short term. The company's strong financial performance and promising growth prospects are likely to support the stock's price.
Long Term Outlook
Jazz Pharmaceuticals has a strong long-term outlook. The company's pipeline of new products and its focus on unmet medical needs are likely to drive growth in the years to come.
Analyst Recommendations
Analysts are bullish on Jazz Pharmaceuticals. The consensus analyst rating is "buy." The average analyst target price is $175.56, which represents a potential upside of 57.5% from the current stock price.
